Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Free Radic Biol Med. 2016 Apr 19;96:67–77. doi: 10.1016/j.freeradbiomed.2016.04.016

Fig. 5.

Fig. 5

Enhancement of regorafenib's and irinotecan's cytotoxicities by DGLA in D5D-KD HCA-7 colony 29 cells. (A) MTS assay for cell proliferation of control siRNA transfected or D5D-KD HCA-7 cells treated with 10 µM regorafenib, regorafenib and 100 µM DGLA, 40 µM irinotecan, and irinotecan with 100 µM DGLA for 48 h. The control siRNA transfected and D5D-KD cells without fatty acid and drug treatment were used as controls. (*: significant difference with p < 0.05 from n ≥ 3); (B) colony formation assay of control siRNA transfected or D5D-KD HCA-7 cells treated with regorafenib (20 µM), regorafenib + DGLA (100 µM), irinotecan (4 µM), irinotecan + DGLA (100 µM). The control siRNA transfected and D5D-KD cells without fatty acid and drug treatment were used as controls (*: significant difference with p < 0.05 from n ≥ 3).